Involved-Site Radiation Therapy if Minimal Toxicity
Treatment approaches for nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) vary widely from observation to combined systemic therapy/radiation therapy (RT).1 Recommendations commonly depend on the disease burden at presentation. Prior studies including pediatric2 and adult3 patients have reported outcomes after observation of resected NLPHL and found 5-year event-free/progression-free survival rates of 77% and 59%, respectively, with no difference in overall survival for observed versus treated patients.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Jillian R. Gunther Tags: Gray Zone Source Type: research
More News: Biology | Cancer & Oncology | Hodgkin's Disease | Lymphoma | Pediatrics | Physics | Radiation Therapy | Radiology | Study | Toxicology